第一作者机构:[1]Fudan Univ, Zhongshan Hosp, Dept Endocrinol & Metab, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Zhao L.,Wen Q.,Zhang Y.,et al.Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1/GIP receptor agonist HRS9531 in T2DM patients[J].DIABETES RESEARCH AND CLINICAL PRACTICE.2024,209:doi:10.1016/j.diabres.2024.111436.
APA:
Zhao, L.,Wen, Q.,Zhang, Y.,Yu, G.,Pan, T....&Li, X..(2024).Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1/GIP receptor agonist HRS9531 in T2DM patients.DIABETES RESEARCH AND CLINICAL PRACTICE,209,
MLA:
Zhao, L.,et al."Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1/GIP receptor agonist HRS9531 in T2DM patients".DIABETES RESEARCH AND CLINICAL PRACTICE 209.(2024)